Thanks to the huge profit of 57 percent since begin this year it's one of the best shares of the biotech sector.
For this year the company from Breda could earn a total revenue around 69,46 million euros. This is according to the average of the analysts' estimates. This is slightly lower than 2019's revenue of 69,78 million euros.
The analysts expect for 2020 a net loss of 440 million euros. According to most of the analysts the company will have a loss per share for this book year of 9,68 euros. Based on this the price/earnings-ratio is -23,29.
For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,05 percent.
Based on the current number of shares arGEN-X 's market capitalization equals 8,11 billion euros. The arGEN-X stock was the past 12 months quite volatile. Since last November the stock is even 72 percent higher. This year the stock price moved between 93 and 241 euro.
Click here for dividend arGEN-X. At 11.27 the stock trades 1,15 percent lower at 225,4 euros.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.